Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Diagnostics › Molecular Diagnostics › Point-of-Care Flu Test From Mesa Biotech May Head to FDA Next Year

Point-of-Care Flu Test From Mesa Biotech May Head to FDA Next Year

May 23, 2016
|
Madeleine Johnson
Premium

NEW YORK (GenomeWeb) – Aiming for a 2017 launch of its handheld molecular testing device and influenza A/B assay, Mesa Biotech has recently made a number of strategic hires with commercialization and leadership experience.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Mar
18
Featured Webinar

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
29
Featured Webinar

Think Globally, Act Locally: The Importance of Coordinated Global and Community Genetic Surveillance Programs

Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Mar
31
Featured Webinar

Development and Commercialization of a Novel CRISPR-Based SARS CoV-2 Test

Sponsored by
MilliporeSigma

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test. 

What's Popular?

In Molecular Diagnostics

  1. AMP Survey Finds Significant Decline in Molecular Cancer Testing Due to COVID-19 Pandemic

  2. Meridian Withdraws Emergency Use Authorization Application to FDA for Coronavirus MDx Test

  3. SARS-CoV-2 Test Pooling Studies Offer Insights for Implementing, Optimizing Approaches

  4. Grail Signs on Quest Diagnostics to Provide Phlebotomy for Cancer Detection Test

  5. Quidel Reports Delay in OTC COVID-19 Antigen Test Claims, Pours Cold Water on M&A Rumors

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.